A detailed history of Murphy & Mullick Capital Management Corp transactions in Novavax Inc stock. As of the latest transaction made, Murphy & Mullick Capital Management Corp holds 50 shares of NVAX stock, worth $409. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50
Holding current value
$409
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$7.22 - $14.68 $361 - $734
50 New
50 $402,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $640M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Murphy & Mullick Capital Management Corp Portfolio

Follow Murphy & Mullick Capital Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Murphy & Mullick Capital Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Murphy & Mullick Capital Management Corp with notifications on news.